CRISPR Therapeutics sinks 11.2% in a single week
CRISPR Therapeutics drops 11.2%, sending the residual capital back into the red
CRISPR Therapeutics sinks 11.2% in a single week
Our view last week
CRISPR Therapeutics is in week 11 of a buy signal, with the trade up 3.6% since entry. All 3 targets of our most advanced model have already been hit and model coverage is complete: residual capital now carries on, with a dynamic stop tighter than the structural level. Signal strength stays medium-weak, in a context of elevated volatility.
This week's summary
CRISPR Therapeutics technical analysis flags a rough week: the stock fell 11.2%, with sellers taking nearly all of the volume and money flow swinging back into negative territory. Price is now boxed into a very tight band, between the first resistance in the 53.5 area and the first support in the 53.3 area, not far from the old double bottom in the 50 area. Last week the residual capital was still in the green; now it's back underwater.
IQS Phase
37
ordinary
Signal Strength
59
medium
Sizing
STANDARD
Ranking
#77 / 129
US stocks in progress
Trade P&L %
-8.00%
from signal to today
restricted Platinum content